| Literature DB >> 35022044 |
Betty Kirkwood1, Lisa Hurt2, Caitlin Shannon3, Chris Hurt4, Seyi Soremekun1, Karen Edmond5, Sam Newton6, Seeba Amenga-Etego7, Charlotte Tawiah-Agyemang7, Zelee Hill8, Alexander Manu9, Ben Weobong10.
Abstract
BACKGROUND: Globally adopted health and development milestones have not only encouraged improvements in the health and wellbeing of women and infants worldwide, but also a better understanding of the epidemiology of key outcomes and the development of effective interventions in these vulnerable groups. Monitoring of maternal and child health outcomes for milestone tracking requires the collection of good quality data over the long term, which can be particularly challenging in poorly-resourced settings. Despite the wealth of general advice on conducting field trials, there is a lack of specific guidance on designing and implementing studies on mothers and infants. Additional considerations are required when establishing surveillance systems to capture real-time information at scale on pregnancies, pregnancy outcomes, and maternal and infant health outcomes. MAIN BODY: Based on two decades of collaborative research experience between the Kintampo Health Research Centre in Ghana and the London School of Hygiene and Tropical Medicine, we propose a checklist of key items to consider when designing and implementing systems for pregnancy surveillance and the identification and classification of maternal and infant outcomes in research studies. These are summarised under four key headings: understanding your population; planning data collection cycles; enhancing routine surveillance with additional data collection methods; and designing data collection and management systems that are adaptable in real-time.Entities:
Keywords: Community; Infant; Maternal; Neonatal; Population-based; Randomised controlled trials; Research; Surveillance
Year: 2022 PMID: 35022044 PMCID: PMC8756712 DOI: 10.1186/s12982-021-00109-0
Source DB: PubMed Journal: Emerg Themes Epidemiol ISSN: 1742-7622
General considerations when establishing a population-based surveillance system for community-based research studies
| • How will the study area be selected? |
| • How will a collaborative relationship be developed and maintained with the community in the area? |
| • Is there an up-to-date census of the population and a map of residences? |
| • How will field staff be selected and trained? |
| • How will the field staff work together, and what supervisory structures are required? |
| • Where will field staff be based, and who will manage the logistics of any field offices and any staff accommodation requirements? |
| • Where will data collection and/or intervention delivery visits take place, and what procedures will be in place for individuals who are not present when a fieldworker calls to collect data? |
| • What supervisory structures will be in place for field staff, and how will these be monitored and evaluated? |
| • How will the information be transferred from the field to the central database, and how will the confidentiality of the information be maintained? |
| • What checks are needed in the field office (before information is sent/uploaded to the central office)? |
| • Who will develop the data management system, when will this be done, and how will it be tested? |
| • What data checks and data reports are required on a regular basis, and who will monitor and act on these (to identify areas for adaptation or improvement)? |
| • Is there capacity for the data management system to evolve to support implementation, and who will be responsible for this? |
See [6] for more detail on each aspect
Description of the surveillance systems used in the three trials
| Trial name | ObaapaVitA | Newhints | Neovita |
|---|---|---|---|
| Trial design | Cluster-randomized, double-blind, placebo-controlled | Cluster-randomized, usual care controls | Individually-randomized, double-blind, placebo-controlled |
| Eligible population | All women in women aged 15–45 years living in seven rural districts in Brong Ahafo Region in Ghana capable of giving informed consent and planning to live in the trial area for at least 3 months | Neonates who were at least two hours old; on the day of birth or in the next two days; able to feed orally; and likely to stay in the area for at least 6 months | |
| Dates of data collection | Phased start by site: 12/2000–10/2008 (Kintampo N and S) 06/2001–10/2008 (Wenchi and Tain) 06/2002–10/2008 (Techiman) 01/2003–10/2008 (Nkoranza N & S) | Surveillance system that had been established for ObaapaVitA continued from 11/2008 to 12/2009 | Enrolment started in 08/2010 Last infant followed to 12 months of age at 11/2012 |
| Frequency of visits | Every 4 weeks, to all enrolled women | Every 4 weeks to all enrolled women In July 2009, because of budget constraints, this frequency was reduced to visits every 8 weeks and restricted to women who were pregnant and infants | All reproductive age women visited every 12 weeks All pregnant women visited every 4 weeks until 8th month of pregnancy and daily in the last month of pregnancy All infants visited every 4 weeks until status of infant at 12 months of age was ascertained |
| Data collection team | Fieldworkers, who were supervised by site leader, co-ordinators, and supervisors; senior supervisors for more complex data collection; dosing supervisors in Neovita | ||
| Tasks completed during fieldworker visits | 1. Collect 4-weekly data 2. Distribute intervention and control capsules 3. Enrol new eligible women (e.g., if they had moved in or turned 15) | 1. Collect 4 weekly data 2. Enrol new eligible women (e.g., if they had moved in or turned 15) | 1. Collect 4- or 12-weekly data |
| Primary outcome(s) | 1. Pregnancy-related mortality 2. All-cause mortality in women of reproductive age | 1.All-cause neonatal mortality | 1. Post-supplementation infant mortality to 6 months of age |
| Secondary outcomes | 1. Severe maternal morbidity 2. Stillbirths 3. Perinatal mortality 4. Neonatal mortality 5. Infant mortality | 1. Age-specific neonatal mortality 2. Cause-specific neonatal mortality 3. Behavioural outcomes (that is, how many women practiced the Newhints behaviours) | 1. Post-supplementation neonatal mortality 2. Post-supplementation infant mortality 3. Post-supplementation neonatal morbidity 4. Adverse events |
| Other data collection or visits | 1. Additional forms completed by supervisors with additional training (e.g., verbal autopsies, adherence) 2. Hospital based surveillance (from 01/2004), to collect data on maternal morbidities | 1. Verbal autopsy forms completed by supervisors with additional training 2. In intervention zones, CBSVs aimed to visit women twice during pregnancy and three times after birth (on days 1, 3, and 7) | 1. Verbal autopsy forms completed by supervisors with additional training 2. Dosing supervisors gave the study capsules to enrolled newborns in the community and in birthing facilities, and collected adverse event data on days 1 and 3 |
Lessons learnt and accompanying checklist for planning the design and implementation of community-based maternal, newborn and infant health studies
| Checklist of items to consider at the planning stage: | Solutions | |
|---|---|---|
| 1. Understand your population | • Conduct formative research to understand the norms around disclosing a pregnancy in your population • Consider fieldworker characteristics, location, training, and supervision, and how these might affect a woman’s likelihood to discuss their pregnancy with them • Conduct formative research to understand behaviours around delivery (in particular, whether women move shortly before and after delivery and how they make plans for delivery) • Collect data from women on their delivery plans (including planned place of residence and place of delivery), so that data collection and intervention delivery issues can be mitigated | |
| 2. Plan your data collection cycle | • Plan for study visits that are as frequent as resources allow • Consider intervention delivery requirements in addition to data collection requirements • Consider the issues that might lead to changes in visit frequency as participants progress through the study (e.g., instigate more frequent visits once a woman is pregnant, or in the later stages of a pregnancy if births need to be detected quickly) • Consider alternative methods of data collection (e.g., contact with key informants, mobile phone use) • Consider whether women need to be enrolled in the surveillance system before the pregnancy outcome (e.g., this may be essential for intervention delivery in some cases, but not in others) • Plan the last visit at a reasonable time after the end of the period of interest (e.g., to capture maternal outcomes at the end of the 6-week postpartum period, plan the visit for the 8–12th week or later if the data collection is not time-sensitive) | |
| 3. Enhance routine surveillance with additional data collection methods | • Consider which additional data sources are useful, including: -Data collection at hospitals or clinics (e.g., for data on morbidities; also good for identifying pregnancies not reported in the field and for confirming dates) -Verbal autopsies (for cause of death information; also good for identifying pregnancies not reported in the field and for confirming dates) • Include resources to employ, train and supervise senior staff to collect data form these additional sources • Incorporate strategies for dealing with inconsistencies between sources a priori into the data cleaning plan • Consider whether additional confirmation is needed for some data (e.g., is a woman’s self-report of a pregnancy adequate or is formal pregnancy testing needed?) | |
| 4. Design a field and data management system that is adaptable in real-time | • Consider whether data collection will be different at different points in the study, and how this can be changed in real-time (e.g., do you want to collect more data from women once they are pregnant?) • Consider whether there needs to be regular changes to work listings (e.g., do you want to collect data on mothers and infants after birth, and should the infant appear on a fieldworker’s work listings?) • Allow for appropriate intervals in the production of work listings (e.g., allowing for mourning periods before collecting verbal autopsy data) • Consider the specific errors that may occur with data collection on mothers and infants and develop a plan that will allow for the correction of these in real-time |
Data collection cycle
| Activity | Week 1 | Week 2 | Week 3 | Week 4 |
|---|---|---|---|---|
| Data collection | FW area 1 | FW area 2 | FW area 3 | FW area 4 |
| Data checks in field office | FW area 4 | FW area 1 | FW area 2 | FW area 3 |
| Data entry; verification; R and C checks | FW area 3 | FW area 4 | FW area 1 | FW area 2 |
| IDBCs; listings and labels printed | FW area 2 | FW area 3 | FW area 4 | FW area 1 |
FW fieldworker (each fieldworker was responsible for 4 fieldwork areas), R and C range and consistency, IDBCs interdatabase checks (for example, checking consistent dates of birth in different databases)